...
首页> 外文期刊>Nutrition and Dietary Supplements >Economic Burden of Osteoporotic Patients with Fracture: Effect of Treatment With or Without Calcium/Vitamin D Supplements
【24h】

Economic Burden of Osteoporotic Patients with Fracture: Effect of Treatment With or Without Calcium/Vitamin D Supplements

机译:骨折骨折患者的经济负担:钙/维生素D补充剂治疗的影响

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background: Fractures represent the most important complication of osteoporosis, in terms of loss of independency, chronic pain, increased risk of mortality, but also high healthcare costs. Objective: To assess healthcare costs in an Italian cohort of osteoporotic patients with a fracture with and without specific osteoporosis treatment and supplementation with calcium/vitamin D. Methods: This retrospective observational study used data from administrative databases of five Local Health Units in Italy. Patients ≥ 50 years of age and hospitalized for vertebral or hip fracture occurring from 01/01/2011 to 31/12/2015 were included. Patients were then classified as “untreated” and “treated” if they had been treated or not with drugs for fracture prevention after the index fracture. We also identified subjects that were only treated with drugs for fracture prevention, “osteoporosis drug only” group, compared to the “osteoporosis drug plus calcium/vitamin D” group, in which calcium and/or vitamin D were also in combination. Healthcare cost analysis included drug expenditure, hospitalization costs (excluding costs related to the hospitalization for the index fracture) and outpatient service costs. Results: Three thousand four hundred and seventy-five patients were included in the present study, most of whom (58.5%) had received specific osteoporosis treatment after index fracture. Among treated patients, the vast majority (83.6%) received supplementation with calcium/vitamin D. Mean annual healthcare cost per patient was € 9,289.85 in the untreated group and € 4,428.26 for treated subjects (p 0.001); mean annual healthcare cost for the osteoporosis drug-only group was higher compared to the osteoporosis drug plus calcium/vitamin D group (€ 5,976.88 vs € 4,124.74, respectively, p 0.001). Hospitalization costs accounted for the majority of total costs in all groups of patients. Conclusion: Healthcare costs in patients with osteoporotic fractures were significantly lower in those receiving osteoporosis treatment compared to untreated patients with even lower costs observed in patients that were also receiving calcium/vitamin D supplements.
机译:背景:骨折代表骨质疏松症最重要的并发症,在独立性丧失,慢性疼痛,死亡率增加,也是高医疗费用。目的:评估意大利骨质疏松患者的医疗保健成本,骨折骨折,骨折,没有特异性骨质疏松症治疗和用钙/维生素D补充。方法:这项回顾性观察研究使用意大利五个当地健康单位的行政数据库数据。患者≥50岁,并为椎体或髋关节骨折住院,包括从01/01/21/21/21-21-2015发生。如果患者被归类为“未经处理的”,并且“治疗”如果在指数骨折后骨折预防药物治疗。我们还确定了仅用骨折预防药物治疗的受试者,“骨质疏松药物仅”组,与“骨质疏松药物加钙/维生素D”组相比,其中钙和/或维生素D也合于组合。医疗成本分析包括毒品支出,住院费用(不包括与住院费用的费用为指数骨折)和门诊服务费用。结果:本研究纳入三千四百七十五名患者,其中大多数(58.5%)在指数骨折后接受了特异性骨质疏松症治疗。在治疗的患者中,绝大多数(83.6%)收到钙/维生素D的补充剂,每位患者的年医疗保健成本是未处理组的9,289.85欧元,€4,428.26治疗受试者(P <0.001);与骨质疏松药物加上钙/维生素D组相比,骨质疏松症的骨质疏松症的年医疗成本较高(分别为5,976.88欧元,P <0.001)。住院费用占所有患者的大多数总费用。结论:与在接受钙/维生素D补充剂的患者中,骨质疏松症治疗相比,接受骨质疏松症治疗的患者的医疗保健费明显降低。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号